chevron_leftBack
As of 13 June 2026, ARS Pharmaceuticals, Inc. has a market cap of $778.49M USD, ranking #12219 globally and #2338 in the United States.
It ranks #1116 in the Healthcare sector, and #415 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$778.49MUSD
Enterprise Value
$687.12MUSD
Revenue (TTM)
$84.28MUSD
EBITDA (TTM)
-$178.08MUSD
Net Income (TTM)
-$171.3MUSD
EBITDA Margin
-211%
Profit Margin
-203%
PS Ratio
9.1
PB Ratio
6.9
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Richard Lowenthal
open_in_new
Employees
163
Founded
2015
Website
ars-pharma.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.3% | -6.7% | -2.9% | -22% | -17% | -45% |
News
Loading...
SPRY Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
SPRY
ARS Pharmaceuticals Inc
ISIN: US82835W1080
Shares Out.:
Shares Outstanding:
99.303M1
Shares Float:
64.502M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
7.84 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
98K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
70K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
46K%
|
97.4
|
|
NYSE: MRK
|
$274.03B
35K%
|
15.1
|
|
NYSE: PFE
|
$149.38B
19K%
|
19.5
|
|
NYSE: BMY
|
$117.58B
15K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
41K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
37K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
35K%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
23K%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
14K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
14K%
80.96B GBP
|
14.6
|
chevron_leftBack